Satellite Symposia
2012 ACCP Annual Meeting

ACCP is pleased to offer satellite symposia as a forum for the presentation of continuing pharmacy education programs developed by other accredited providers. The following programs are available for continuing pharmacy education credit, and admission is free to meeting registrants.

Monday, October 22

Targeting Hyponatremia: Reducing Risk, Improving Outcomes

Registration and Breakfast
6:30 a.m.–7:00 a.m.

Satellite Symposium
7:00 a.m.–9:00 a.m.

Location:
Great Hall 2
Westin Diplomat Resort

Program Overview:
Hyponatremia—one of the most common electrolyte disturbances encountered in clinical practice—has a significant impact on both health systems and patients. Diagnosis can be challenging, since symptoms can be subtle and nonspecific. Management is complicated by the fact that traditional therapies are only moderately effective, are difficult for patients to comply with, and/or are associated with potential serious adverse effects. The recent introduction of new pharmacotherapeutic options targeting the underlying pathophysiology is beginning to change the paradigm for management of this condition.

Clinical pharmacists, as expert consultants, play a pivotal role in patient monitoring and selection of the most appropriate therapeutic option based on cost and safety data as well as the cost of ineffective treatment. This 2-hour, case-enhanced symposium is designed to provide clinical pharmacists with a thorough understanding of the diagnosis, pathophysiology, and both short- and long-term management of this common condition.

Learning Objectives:
After completing this live, knowledge-based activity, participants should be better able to:

• Identify signs and symptoms of hyponatremia in hospitalized patients by understanding their underlying etiology;
• Examine the prevalence as well as the clinical and economic consequences of hyponatremia; and
• Evaluate the pharmacology, efficacy, and safety of conventional and newer agents for short- and long-term treatment.

Agenda & Faculty:
6:30 a.m.–7:00 a.m.  Registration and Breakfast
7:00 a.m.–7:05 a.m.  Welcome and Introductions
  J. Herbert Patterson, Pharm.D., FCCP, Chair
7:05 a.m.–7:25 a.m.  Classification, Epidemiology, and Clinical Burden
  J. Herbert Patterson, Pharm.D., FCCP
7:25 a.m.–8:00 a.m.  Pathophysiology: Alterations in the Water-Sodium Balance
  Michael F. Michelis, M.D.
8:00 a.m.–8:40 a.m.  Correcting Hyponatremia Safely and Effectively
  Denise H. Rhoney, Pharm.D., FCCM, FCCP

8:40 a.m.–9:00 a.m.  Panel Case Discussion and Questions and Answers
  All faculty, Moderated by Chair

J. Herbert Patterson, Pharm.D., FCCP (Chair)
Professor of Pharmacy and Research Professor of Medicine
Executive Vice Chair
Division of Pharmacotherapy and Experimental Therapeutics
University of North Carolina Eshelman School of Pharmacy
Chapel Hill, North Carolina, USA

Michael F. Michelis, M.D.
Clinical Professor of Medicine
New York University School of Medicine
Director of Nephrology
Lenox Hill Hospital
New York, New York, USA

Denise H. Rhoney, Pharm.D., FCCM, FCCP
Associate Professor and Chair
Division of Pharmacy Practice and Experiential Education
University of North Carolina Eshelman School of Pharmacy
Chapel Hill, North Carolina, USA

Target Audience:
This activity has been designed to meet the educational needs of pharmacists interested in the management of patients with hyponatremia.

Continuing Pharmacy Education Credit:
This activity is co-sponsored by the University of North Carolina Eshelman School of Pharmacy and Paradigm Medical Communications, LLC.

Accreditation Statement
The University of North Carolina Eshelman School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
This program, 0046-9999-12-148-L01-P, will provide 2.0 contact hours or 0.2 CEUs for attending this live activity and for completing an evaluation form. Credit statements will be mailed within 2-4 weeks to participants who have completed the program evaluation.

Type of Activity:
Knowledge-based

Statement of Support:
This CPE activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc.
Registration Information:
Seating at the symposium is limited and will be on a first-come, first-served basis. Pre-registration is not required, but is strongly encouraged. There is no registration fee to attend.
If you would like to participate in this activity, please register online or by telephone.


Phone (Toll-free): 877-252-5100, ext 4

Tuesday, October 23

The Role of the Clinical Pharmacist as a Catalyst for Appropriate Antibiotic Decision Making in 2012 and Beyond: Focus on ABSSSI and CABP

Registration and Breakfast
6:30 a.m.–7:00 a.m.

Satellite Symposium
7:00 a.m.–8:35 a.m.

Location:
Great Hall 2
Westin Diplomat Resort

Program Overview:
Effective management of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP)—two common and serious infections—is becoming particularly difficult in light of ever-increasing antimicrobial resistance among key pathogens, a limited anti-infective pipeline, and evolving financial pressures imposed on the healthcare system by federal ‘mandates’ such as the new 2012 Joint Commission/Centers for Medicare and Medicaid Services Pneumonia Core Measures.

Clinical pharmacists, as expert consultants, play a pivotal role in facilitating appropriate antibiotic use by ensuring selection of the agent, older or new, that is most likely to provide coverage for the most likely causative pathogen while minimizing development of resistance. This symposium is designed to increase participant knowledge of current clinical evidence, pertinent guidelines, and performance quality measures to help them ensure optimal management of patients with ABSSSI and CABP.

Learning Objectives:
After completing this activity, the participant should be better able to:

- Describe current evidence-based approaches for management of ABSSSIs with or without MRSA, and the decision process used when selecting an appropriate antibiotic;
- Recognize current evidence-based approaches for management of CABP, including consensus recommendations for appropriate incorporation of newer antibiotics; and
- Discuss novel strategies for ensuring appropriate antibiotic use and for preserving antibiotic efficacy.

Agenda & Faculty:
6:30 a.m. – 7:00 a.m.  Registration and Breakfast
7:00 a.m. – 7:05 a.m.  Welcome and Introductions
   Neil A. Davis, Pharm.D., Chair

7:05 a.m. – 7:30 a.m.  Evidence-based Antibiotic Therapy for ABSSSI—More than Skin Deep
   Neil A. Davis, Pharm.D.

7:30 a.m. – 7:55 a.m.  Evidence-based Management of CABP—Quality Matters
   Donald E. Low, M.D., FRCPC

7:55 a.m. – 8:20 a.m.  Appropriate Antibiotic Use: Evidence-based Strategies for Deciding Among the Old and the New
   Timothy R. Pasquale, Pharm.D.

8:20 a.m. – 8:35 a.m.  Question and Answers/Panel Discussion: Taking Action to Change Practice
   All faculty, Moderated by Chair

Neil A. Davis, Pharm.D. (Chair)
Associate Clinical Professor
Virginia Commonwealth University
Richmond, Virginia, USA
Critical Care Clinical Specialist
Clinical Pharmacy Coordinator
Sentara Healthcare
Virginia Beach, Virginia, USA

Timothy R. Pasquale, Pharm.D.
Clinical Lead, Infectious Disease
Summa Health System
Akron, Ohio, USA

Donald E. Low, M.D., FRCPC
Microbiologist-in-Chief
Department of Microbiology
Mount Sinai Hospital
Professor, University of Toronto
Toronto, Ontario, Canada

Target Audience:
The educational design of this activity addresses the needs of clinical pharmacists involved in the treatment of patients with ABSSSI or CABP.

Continuing Pharmacy Education Credit:
This activity is co-sponsored by Global Education Group and Paradigm Medical Communications, LLC.

Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Global Education Group designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing pharmacy education. (Universal Activity Number: 0530-9999-12-029-L04-P)
In order to receive credit for this activity, the participant must attend the live activity and return a completed evaluation form. Credit statements will be mailed within 6-8 weeks to participants who have completed the program evaluation.

**Type of Activity:**
This is a knowledge-based activity.

**Statement of Support:**
This CPE activity is supported by an educational grant from Forest Laboratories, Inc.

**Registration Information:**
Seating at the symposium is limited and will be on a first-come, first-served basis. Pre-registration is not required, but is strongly encouraged. There is no registration fee to attend.

If you would like to participate in this activity, please register online or by telephone.


Phone: (Toll-free): 877-252-5100, ext 2

---

**Tuesday, October 23**

**The Pharmacist’s Role in ACS Management: Translating Data into Practice**

**Registration and Breakfast**
7:00 a.m.–7:30 a.m.

**Satellite Symposium**
7:30 a.m.–9:00 a.m.

**Location:**
Great Hall 1
Westin Diplomat Resort

**Program Overview:**
There are 1.2 million hospitalizations for acute coronary syndrome (ACS) annually, with myocardial infarctions accounting for 829,000 of these events. Despite the existence of validated consensus guidelines jointly published by the American College of Cardiology (ACC) and American Heart Association (AHA), 25% of opportunities to provide guideline-recommended care are missed in current practice. The failure to adhere to these guidelines is associated with a significant increase in in-hospital mortality and the subsequent development of heart failure. Antiplatelet therapy is essential to the treatment of patients who have ACS, but mainstay antiplatelet options do not always provide an optimal response. This activity will provide pharmacists with the tools necessary to appropriately select and apply antiplatelet agents, and provide validated, guideline-directed care in ACS.

**Learning Objectives:**
At the conclusion of this application-based activity, participants will be able to:

- Review the pathophysiology of ACS and identify the role of antiplatelet agents in the treatment of ACS, focusing on the concepts of importance of aspirin dose, variability of response, and the utility of monitoring of response to thienopyridines;
- Evaluate the risks and benefits of new and traditional treatment options, focusing on monotherapy and combination therapy, bleeding risks, aspirin-dose, drug interactions, and patient/prescriber education points;
- Review guidelines related to the treatment of ACS and examine recommendation trends in recently released and updated guidelines; and
- Using a case-based approach, implement the role for newer antiplatelet therapies to improve patient outcomes in ACS.

**Agenda & Faculty:**

7:00 a.m.–7:30 a.m.  Registration and Breakfast
7:30 a.m.–7:35 a.m.  Welcome and Introductions  
Sarah A. Spinler, Pharm.D., FCCP, BCPS, FASHP (Activity Chair)
7:35 a.m.–8:00 a.m.  ACS from A to Z: Pathophysiology, Current Issues and Advances in Treatment  
Paul P. Dobesh, Pharm.D., FCCP, BCPS
8:00 a.m.–8:25 a.m.  Integrating ACS Guidelines into Practice  
Glenn N. Levine, M.D., FACC, FAHA
8:25 a.m.–8:50 a.m.  Interactive Clinical Cases in Antiplatelet Therapy: Highlighting the Role of the Pharmacist  
Moderated by Sarah A. Spinler; Interactive Panel Discussion
8:50 a.m.–9:00 a.m.  Conversations with the Experts: Audience Questions and Answers

**Sarah A. Spinler, Pharm.D., FCCP, FCPP, FAHA, FASHP, AACC, BCPS (AQ Cardiology) (Activity Chair)**
Professor of Clinical Pharmacy  
Philadelphia College of Pharmacy and Science  
University of Sciences in Philadelphia  
Philadelphia, Pennsylvania, USA

**Paul P. Dobesh, Pharm.D., FCCP, BCPS (AQ Cardiology)**
Associate Professor of Pharmacy Practice  
College of Pharmacy  
University of Nebraska Medical Center  
Omaha, Nebraska, USA

**Glenn N. Levine, M.D., FACC, FAHA**
Professor of Medicine  
Baylor College of Medicine  
Director, Cardiac Care Unit  
Michael E. DeBakey Medical Center  
Houston, Texas, USA

**Target Audience:**
Pharmacists involved in the management of patients with acute coronary syndromes.

**Continuing Pharmacy Education Credit:**

**Accreditation Statement**
Creative Educational Concepts, Inc. (CEC) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

**Credit Designation**
This activity has been assigned ACPE #0245-0000-12-008-L01-P and will award 1.5 contact hours (0.15 CEUs) of continuing pharmacy education credit. CEC complies with the Criteria for Quality for continuing education programming.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be mailed to participants within 10 business days.

**Type of Activity:**
This is an application-based activity.
Statement of Support:
This activity is supported by an independent educational grant from AstraZeneca.

Registration Information:
Seating at the symposium is limited and will be on a first-come, first-served basis. Pre-registration is not required, but is strongly encouraged. There is no registration fee to attend.

If you would like to participate in this activity, please register online or by telephone.

Online: www.ceconcepts.com/ACCP

Phone: (Toll-free): 1-866-360-1717